ECHO IQ LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.15 AUD | +11.11% |
|
+20.00% | -11.76% |
| 01:45am | Echo IQ Launches Heart Failure Detection Study with AI | MT |
| May. 07 | Echo IQ Lodges US FDA Application for EchoSolv Market Clearance; Shares Fall 4% | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
EchoIQ Limited is an Australia-based artificial intelligence (AI) and medical technology company. It uses AI-driven technology and proprietary software to improve decision-making in cardiology. The principal activity of the Company is the development of AI products for cardiovascular care. The Company operates through two segments: Echo IQ and Houston We Have Software. The Echo IQ segment is engaged in developing products and services in medical technology. The Houston We Have Software segment offers products and services across other sectors. Its EchoSolv product allows users to assess echocardiographic studies against diagnostic guidelines for structural heart conditions. EchoSolv automatically identifies patients at risk of structural heart disease. EchoSolv improves the standard clinical workflow associated with diagnosis and treatment. The first two conditions addressed by the product are Aortic Stenosis and Mitral Regurgitation.
Calendar
2024-08-28
- Q4 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -11.76% | 44.64M | |
| +17.56% | 8.09B | |
| +31.92% | 4.3B | |
| -30.37% | 2.63B | |
| -18.51% | 1.41B | |
| -24.69% | 1.31B | |
| -33.58% | 1.15B | |
| +11.87% | 1B | |
| -33.89% | 924M | |
| -20.99% | 676M |
- Stock Market
- Equities
- EIQ Stock
- News Echo IQ Limited
- Respiri Signs Deal to Integrate Echo IQ’s Cardiovascular Technology to Remote Monitoring System; Shares Fall 4%